Review
Oncology
Stefania Rizzo, Isabel Scala, Angela Rodriguez Robayo, Marco Cefali, Sara De Dosso, Stefano Cappio, Genti Xhepa, Filippo Del Grande
Summary: This systematic review examines the association between body composition and chemotherapy-related toxicity in pancreatic cancer patients, and evaluates the different definitions of sarcopenia. The results show a wide variability in the association between body composition and chemotherapy-related toxicity in PC patients, and there is no uniform definition for sarcopenia.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Stefania Rizzo, Giorgio Raia, Maria Del Grande, Maria Luisa Gasparri, Ilaria Colombo, Lucia Manganaro, Andrea Papadia, Filippo Del Grande
Summary: This systematic review examined the association between image-based body composition and chemotherapy-related toxicity in ovarian cancer patients. The results showed a wide variability in the association, and there were inconsistent definitions of sarcopenia. Further studies are needed to better understand this association.
FRONTIERS IN ONCOLOGY
(2022)
Article
Nutrition & Dietetics
Susie Youn, Angela Chen, Vincent Ha, Carole Chambers, Dean T. Eurich, Michael McCall, Michael B. Sawyer
Summary: The study found that adjusting nab-paclitaxel doses based on muscle mass can predict the risk of chemotherapy toxicity. Factors like BMI, body surface area, and initial drug doses did not significantly impact toxicity occurrence.
CLINICAL NUTRITION
(2021)
Article
Geriatrics & Gerontology
Sylvia Saalfeld, Robert Kreher, Georg Hille, Uli Niemann, Mattes Hinnerichs, Osman Oecal, Kerstin Schuette, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Thomas Berg, Heinz J. Kluempen, Julia Benckert, Antonio Gasbarrini, Holger Amthauer, Bruno Sangro, Peter Malfertheiner, Bernhard Preim, Jens Ricke, Max Seidensticker, Maciej Pech, Alexey Surov
Summary: This study analyzed the prognostic potential of radiomics-based parameters of the skeletal musculature and adipose tissues in patients with advanced hepatocellular carcinoma (HCC). The results showed that these parameters can predict 1-year survival in HCC patients, with higher prognostic value in patients who received SIRT and sorafenib treatment.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Editorial Material
Oncology
Ryan Fecteau, W. Robert Lee
Summary: Patients with nonmetastatic, high-risk prostate cancer have a higher likelihood of dying from causes unrelated to their cancer. Identifying patients at greater risk from competing risks is crucial for treatment decision-making.
Article
Nutrition & Dietetics
Emanuele Rinninella, Antonia Strippoli, Marco Cintoni, Pauline Raoul, Raffaella Vivolo, Mariantonietta Di Salvatore, Enza Genco, Riccardo Manfredi, Emilio Bria, Giampaolo Tortora, Antonio Gasbarrini, Carmelo Pozzo, Maria Cristina Mele
Summary: The study found that a high proportion of gastric cancer patients receiving FLOT therapy had muscle wasting, and preoperative FLOT treatment further reduced patients' muscle mass, body mass index, and visceral adipose index. However, these changes were not significantly associated with short-term treatment outcomes.
Article
Geriatrics & Gerontology
Saliu A. Balogun, Dawn Aitken, Feitong Wu, David Scott, Graeme Jones, Tania Winzenberg
Summary: This study aimed to describe the relationships between physical activity, body composition, and multimorbidity over 10 years in older adults. The results showed a nonlinear relationship between physical activity level and multimorbidity, with lower risk associated with less steps per day, as well as linear associations between higher BMI, fat mass, lower grip strength, and lean mass with higher risk of multimorbidity. Maintaining adequate physical activity levels and muscle function while reducing adiposity may help minimize the risk of multimorbidity in older adults.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2021)
Article
Multidisciplinary Sciences
R. Mallet, P. Decazes, R. Modzelewski, J. Lequesne, P. Vera, B. Dubray, S. Thureau
Summary: Low skeletal muscle mass is a strong prognostic factor in non-small-cell lung cancer patients treated with radiochemotherapy. The automatic software Anthropometer3D can identify high-risk patients who may benefit from tailored therapy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
Summary: This study investigated the influence of pheochromocytoma on human body composition, revealing that sympathetic hyperactivity may contribute to increased lipolysis in visceral and subcutaneous adipose tissues but has an unclear impact on human skeletal muscle.
Article
Medicine, General & Internal
Silvia Catanese, Giacomo Aringhieri, Caterina Vivaldi, Francesca Salani, Saverio Vitali, Irene Pecora, Valentina Massa, Monica Lencioni, Enrico Vasile, Rachele Tintori, Francesco Balducci, Alfredo Falcone, Carla Cappelli, Lorenzo Fornaro
Summary: This study retrospectively assessed body composition parameters for 78 aGC patients undergoing palliative treatment, finding that VFA/SFA had a stronger impact on survival with higher sensitivity than sarcopenia.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Nutrition & Dietetics
P. J. Navin, M. R. Moynagh, E. J. Atkinson, P. Tirumanisetty, N. K. LeBrasseur, A. Kumar, S. Khosla, N. Takahashi
Summary: This study utilized CT data to determine age and sex specific distribution of body composition, providing important reference for future research and clinical practice.
CLINICAL NUTRITION
(2021)
Article
Nutrition & Dietetics
A. Casirati, G. Vandoni, S. Della Valle, G. Greco, M. Platania, S. Colatruglio, L. Lalli, C. Gavazzi
Summary: The study found that malnutrition expressed as weight loss (WL) was more in agreement with sarcopenia recognized using CT than BIA method. Further research is needed to confirm these findings and identify the best methods for monitoring body composition during nutritional intervention and cancer therapies.
CLINICAL NUTRITION
(2021)
Article
Nutrition & Dietetics
Daniel Haigis, Leon Matting, Silas Wagner, Gorden Sudeck, Annika Frahsa, Ansgar Thiel, Gerhard Eschweiler, Andreas Michael Niess
Summary: The study found a low prevalence of sarcopenic obesity among elderly residents in nursing homes. However, sarcopenia and obesity still play important roles in maintaining the health of residents.
Article
Nutrition & Dietetics
Lijuan Wang, Pengxue Li, Yifu Hu, Bo Cheng, Lili Ding, Lei Li, Jinghai Song, Junmin Wei, Jingyong Xu
Summary: This study analyzed the correlation between preoperative nutritional status, frailty, sarcopenia, body composition, and anthropometry in geriatric inpatients undergoing major pancreatic and biliary surgery. The study found a high prevalence and overlap rates of malnutrition, frailty, and sarcopenia in elderly inpatients, with body composition and function deteriorating with aging. Age and malignancy affected the nutrition diagnosis.
FRONTIERS IN NUTRITION
(2023)
Review
Nutrition & Dietetics
Junjie Wang, Shanjun Tan, Luca Gianotti, Guohao Wu
Summary: Wasting in cancer patients adversely affects their quality of life, treatment tolerance, and oncological outcomes. Evaluating this condition solely based on body weight is not accurate, as it includes changes in all body compartments and may be masked by conditions such as edema and ascites. Historically, body composition assessment in cancer patients has been underappreciated due to limited measurement tools. However, as the importance of body composition is increasingly recognized, a more precise evaluation and targeted approach to nutritional support for cancer patients is crucial.
Article
Oncology
Apostolia M. Tsimberidou, Elena Fountzilas, Leonidas Bleris, Razelle Kurzrock
Summary: Transcriptomics is a valuable tool in understanding cancer mechanisms and identifying biomarkers. It enables the analysis of gene expression and identification of molecular alterations in tumor tissue, which can be used for clinical interventions. It also has applications in predicting and prognosticating biomarkers, improving risk stratification, and understanding the impact of genomic alterations. Additionally, transcriptomics can be used to identify markers predicting response to immunotherapy in clinical trials.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Apostolia M. Tsimberidou, Peter Muller, Yuan Ji
Summary: Genomic profiling technologies have enabled precision oncology studies and clinical trials that target specific biomarkers and molecular pathways. Innovative clinical trial designs aim to achieve personalized treatment and accelerate drug development, but statistical conclusions may be limited due to small subpopulations of patients.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Health Care Sciences & Services
Jose Pereira, Lynn Meadows, Dragan Kljujic, Tina Strudsholm, Henrique Parsons, Brady Riordan, Jonathan Faulkner, Kathryn Fisher
Summary: This study aimed to explore the learning experience of learners from different professions who participated in the Learning Essential Approaches to Palliative Care Core courses. The results showed that the majority of learners agreed that the course was relevant to their practice, with some differences observed among different profession groups. Curriculum design should be tailored to meet the specific learning needs of different professions.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
(2022)
Article
Health Care Sciences & Services
James Downar, Henrique A. Parsons, Leila Cohen, Ella Besserer, Samantha Adeli, Valerie Gratton, Rebekah Murphy, Grace Warmels, Adrianna Bruni, Khadija Bhimji, Claire Dyason, Paula Enright, Isabelle Desjardins, Krista Wooller, Monisha Kabir, Chelsea Noel, Brandon Heidinger, Koby Anderson, Kyle Arsenault-Mehta, Julie Lapenskie, Colleen Webber, Daniel Bedard, Akshai Iyengar, Shirley H. Bush, Sarina R. Isenberg, Peter Tanuseputro, Brandi Vanderspank-Wright, Peter Lawlor
Summary: Severe grief symptoms are common among family members who have lost loved ones during the COVID-19 pandemic, regardless of the cause or timing of death. This suggests that specific factors related to the pandemic contribute to severe grief, and traditional methods of mitigating grief may not be as effective.
PALLIATIVE MEDICINE
(2022)
Article
Oncology
Aung Naing, Alain P. Algazi, Gerald S. Falchook, Benjamin C. Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B. Mettu, Pierre L. Triozzi, John Hamm, Gongfu Zhou, Chris Walker, Zhiwan Dong, Manish R. Patel
Summary: This study evaluated the safety and efficacy of the combination therapy of the IDO1 inhibitor epacadostat and the PD-L1 monoclonal antibody durvalumab in patients with advanced solid tumors. The study findings showed that the combination therapy had common adverse events and low objective response rate, and a higher dose of epacadostat was needed for sufficient drug effect.
Article
Oncology
Justin T. Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A. Yap, Daniel Karp, Jordi Rodon, Andy Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Joseph Ludwig, Cynthia Herzog, Ravin Ratan, Neeta Somaiah, Anthony Conley, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Summary: In this study, the outcomes of patients with ultrarare sarcomas in Phase 1 trials were assessed. The results showed that the median overall survival of ultrarare sarcomas was similar to common sarcomas, but the objective response rate to treatment was higher. Genomic selection played a significant role in identifying molecular subsets likely to benefit from targeted therapy in Phase 1 trials.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Apostolia Maria Tsimberidou, Claire F. Verschraegen, Robert Wesolowski, Chi-Sheng Shia, Pei Hsu, Tillman E. Pearce
Summary: This is a report of a phase 1 dose-escalation study of OBI-3424 monotherapy in patients with advanced solid tumors. The study used a classic 3 + 3 design to determine the maximum tolerated dose and recommended phase 2 dose of OBI-3424. The results showed that OBI-3424 was well tolerated, with dose-limiting hematologic toxicities observed at the 12 mg/m(2) dose.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-Gonzalez, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Summary: IMA101 is an actively personalized, multi-targeted adoptive cell therapy that targets novel peptide-HLA cancer targets. The treatment was feasible and well tolerated, but no objective responses were observed. The study suggests the need for further evaluation of multi-targeted ACT approaches using high-avidity TCRs.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Oncology
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S. Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John V. Heymach, Funda Meric-Bernstam, Vivek Subbiah
Summary: Combined BRAF + MEK inhibition has been approved by FDA for solid tumors with BRAF V600E mutation, except for colorectal cancer. However, besides MAPK-mediated resistance, there are other mechanisms of resistance, such as activation of CRAF, ARAF, MET, P13K/AKT/mTOR pathway. In the VEM-PLUS study, a pooled analysis of four phase one studies was conducted to evaluate the safety and efficacy of vemurafenib monotherapy and combination regimens in advanced solid tumors with BRAF V600 mutations. The results showed that compared to vemurafenib monotherapy, combinations of vemurafenib with targeted therapies or cytotoxic chemotherapy did not significantly improve overall survival (OS) or progression-free survival (PFS) of patients with BRAF V600E-mutant solid tumors.
NPJ PRECISION ONCOLOGY
(2023)
Review
Oncology
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang, Apostolia M. Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A. Yap, David S. Hong, Ming Sun, Yunfang Jiang, Shubham Pant, Amishi Y. Shah, Amado Zurita, Nizar M. Tannir, Raghunandan Vikram, Jason Roszik, Funda Meric-Bernstam, Vivek Subbiah
Summary: Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. In a clinical trial, patients with mTOR pathway aberrant tumors were treated with sapanisertib, carboplatin, and paclitaxel. The study showed that the combination therapy had manageable safety and preliminary antitumor activity in advanced malignancies with mTOR pathway alterations.
NPJ PRECISION ONCOLOGY
(2023)
Review
Oncology
Christian Rolfo, Elisa Giovannetti, Pablo Martinez, Shannon McCue, Aung Naing
Summary: Toll-like receptors (TLRs) play a crucial role in the immune system and have the potential to be targeted for cancer therapies. TLRs are involved in the defense against microbes and induce immune responses. By combining TLR agonists with immune checkpoint inhibitors, it is possible to convert cold tumors into hot tumors, improving treatment outcomes. Imiquimod is a TLR7 agonist approved for antiviral and skin cancer treatments, and several other TLR adjuvants are being used in vaccines. Many TLR agonists are currently being developed as monotherapy or in combination with immune checkpoint inhibitors for solid tumors.
NPJ PRECISION ONCOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Apostolia M. Tsimberidou, Mehmet A. Baysal, Abhijit Chakraborty, Borje S. Andersson
Summary: This study developed a personalized autologous T-cell therapy program for advanced cancer patients. The treatment showed promising results with a high rate of disease stabilization and prolonged disease control in some patients. The feasibility and tolerability of IMA101 were demonstrated, highlighting the potential of multi-targeted adoptive cell therapy for further investigation.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Elena Fountzilas, Henry Hiep Vo, Peter Mueller, Razelle Kurzrock, Apostolia-Maria Tsimberidou
Summary: A literature search was conducted in PubMed to identify phase I/II clinical trials with FDA-approved immunotherapy drugs from 2018 to 2020, and relevant data were compiled for analysis.
